Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Period	Net Profit Margin
2022-12-31	-892.38%
2023-12-31	12.94%
2024-12-31	-345.36%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMLX	$16.84	+3.47%	0.88M
3
4
5

Amylyx Pharmaceuticals Inc. (AMLX) Profit Margin

Profit Margin Data

Get Amylyx Pharmaceuticals Inc. Data in Excel

More AMLX Financial Data